◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT07145411 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ossium Health, Inc. |
| Condition | Bone Marrow Transplant (BMT) |
| Study Type | OBSERVATIONAL |
| Enrollment | 10 participants |
| Start Date | 2024-06-27 |
| Primary Completion | 2027-08 |
Trial Parameters
Condition Bone Marrow Transplant (BMT)
Sponsor Ossium Health, Inc.
Study Type OBSERVATIONAL
Phase N/A
Enrollment 10
Sex ALL
Min Age 12 Years
Max Age 80 Years
Start Date 2024-06-27
Completion 2027-08
Interventions
Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product
Eligibility Criteria
Inclusion Criteria: Patients aged 12-80 may be eligible\* to receive bone marrow for transplantation through the Ossium HOPE Program if: Their treating physician determined they are eligible for allogeneic bone marrow transplant Their treating physician determined that the potential benefit outweighs the potential risks
Related Trials
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology